|
(Health-NewsWire.Net, August 04, 2015 ) Migraine - Pipeline Review, H1 2015
RnRMarketResearch.com Adds “Migraine - Pipeline Review, H1 2015” which provides an overview of the Migraine therapeutic pipeline.
This report gives broad information on the healing progression for Migraine, complete with comparable examination at diverse stages, therapeutics evaluation by pharmaceutical target, segment of action (MoA), course of association (RoA) and molecule sort, nearby latest upgrades, and highlighted news and press releases. It moreover reviews key players included in the supportive progression for Migraine and phenomenal segments on late-organize and stopped endeavours.
The report enhances decision making capacities and help to make convincing counter strategies to expand high ground. It strengthens R&D pipelines by perceiving new targets and MOAs to convey first-in-class and best-in-class things.
Complete report on H1, 2015 Pipeline Review of “Migraine” addition with 70 market data tables and 17 figures, spread across 199 pages is http://www.rnrmarketresearch.com/migraine-pipeline-review-h1-2015-market-report.html .
This report highlights investigational pharmaceuticals from across over globe covering more than 20 treatment ranges and just about 3,000 signs. The report is amassed using data and information sourced from our prohibitive databases, Company/University destinations, SEC filings, money related pro presentations and highlighted press releases from association/school districts and industry-specific pariah sources, set up together by our gathering. Drug profiles/records included in the report encounters infrequent updation taking after a stringent plan of methods that ensures that each one of the profiles are upgraded with the latest course of action of information. Besides, systems including live news & courses of action taking after, project based prepared box and clinical trials registries taking after insurance that the most recent upgrades are gotten on a steady preface.
Companies Discussed/Mentioned in this Research:
Ache Laboratorios Farmaceuticos S/A, Acorda Therapeutics, Inc., Alder Biopharmaceuticals Inc., Allergan, Inc., Amgen Inc., Astellas Pharma Inc., BioDelivery Sciences International, Inc., Biofrontera AG, Bristol-Myers Squibb Company, Charleston Laboratories, Inc., CoLucid Pharmaceuticals, Inc., D-Pharm Ltd., Dr. Reddy's Laboratories Limited, Eli Lilly and Company, Heptares Therapeutics Limited, iCeutica, Inc., Mallinckrodt Plc, Medestea Research & Production S.p.A., Merck & Co., Inc., Monosol Rx, LLC, NAL Pharmaceuticals Ltd., Nektar Therapeutics, NeurAxon, Inc., Northern Light Pharmaceuticals AB, Noxxon Pharma AG, Otsuka Holdings Co., Ltd., Paladin Labs Inc., Pantarhei Bioscience BV, Pivot Pharmaceuticals Inc, Pozen, Inc., RedHill Biopharma Ltd., Revance Therapeutics, Inc., Shin Nippon Biomedical Laboratories, Ltd., Suda Ltd, Teva Pharmaceutical Industries Limited, TheraJect, Inc., Trevena, Inc. and Trigemina, Inc.
Drugs Profile Discussed in this Research :
dextromethorphan hydrobromide + quinidine sulfate), (naproxen sodium + naratriptan hydrochloride), (sumatriptan succinate + naproxen sodium), AA-71, ALD-403, AMG-334, BEMA Triptan, BF-1, C-012, CLH-1T, corticotropin, CVT-427, Deina, DFN-02, DFN-11, DFP-02, dihydroergotamine mesylate, dihydroergotamine mesylate, DORA-12, DP-VPA, esterol, histamine dihydrochloride, ICE-1209, ICE-1210, ICE-1211, IPX-232, ketoprofen, lasmiditan succinate, LY-2951742, NKTR-192, NOXL-41, NXN-188, NXN-462, oxytocin, P-003, picotamide, Protein to Activate Insulin Like Growth Factor 1 Receptor for Migraine, Rimegepant sulfate, rizatriptan benzoate, rizatriptan benzoate, rizatriptan benzoate, RT-001, Small Molecule to Antagonize CGRP for Migraine, Small Molecule to Antagonize CGRP Receptor for Migraine, Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus, Small Molecule to Inhibit nNOS/NET for Migraine and Neuropathic Pain, Small Molecule to Inhibit Prostaglandin E2 for Pain, Small Molecules to Inhibit 5-HT2B and 5-HT7 Receptors for IBS and Migraine, Small Molecules to Inhibit CGRP Receptor for Migraine, Small Molecules to Inhibit Nitric Oxide Synthase for CNS Disorders, SST-8055, sumatriptan succinate, TEV-48125, Tribarcina, TRV-250, zolmitriptan and zolmitriptan
Inquire before buying for this report http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=397264 . (This is a premium report price at US$2000 for a single user PDF license)
Scope :
• The report provides a snapshot of the global therapeutic landscape of Migraine
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Migraine pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products
Reasons to buy :
• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Migraine
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Migraine pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Explore More Research Report on Neurology Therapeutics Market.
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
RnR Market Research
Ritesh Tiwari
+ 18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
